



LJMU Research Online

Wood, S, Harrison, SE, Judd, N, Bellis, MA, Hughes, K and Jones, A

The impact of behavioural risk factors on communicable diseases: a systematic review of reviews

<http://researchonline.ljmu.ac.uk/id/eprint/18621/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Wood, S, Harrison, SE, Judd, N, Bellis, MA, Hughes, K and Jones, A (2021) The impact of behavioural risk factors on communicable diseases: a systematic review of reviews. BMC Public Health, 21 (1). ISSN 1471-2458

LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

<http://researchonline.ljmu.ac.uk/>

RESEARCH ARTICLE

Open Access



The impact of behavioural risk factors on communicable diseases: a systematic review of reviews

Sara Wood¹, Sophie E. Harrison^{2,3}, Natasha Judd^{1,2}, Mark A. Bellis^{1,2*} , Karen Hughes^{1,2} and Andrew Jones⁴

Abstract

Background: The coronavirus (COVID-19) pandemic has highlighted that individuals with behavioural risk factors commonly associated with non-communicable diseases (NCDs), such as smoking, harmful alcohol use, obesity, and physical inactivity, are more likely to experience severe symptoms from COVID-19. These risk factors have been shown to increase the risk of NCDs, but less is known about their broader influence on communicable diseases. Taking a wide focus on a range of common communicable diseases, this review aimed to synthesise research examining the impact of behavioural risk factors commonly associated with NCDs on risks of contracting, or having more severe outcomes from, communicable diseases.

Methods: Literature searches identified systematic reviews and meta-analyses that examined the association between behavioural risk factors (alcohol, smoking, illicit drug use, physical inactivity, obesity and poor diet) and the contraction/severity of common communicable diseases, including infection or associated pathogens. An a priori, prospectively registered protocol was followed (PROSPERO; registration number CRD42020223890).

Results: Fifty-three systematic reviews were included, of which 36 were also meta-analyses. Reviews focused on: tuberculosis, human immunodeficiency virus, hepatitis C virus, hepatitis B virus, invasive bacterial diseases, pneumonia, influenza, and COVID-19. Twenty-one reviews examined the association between behavioural risk factors and communicable disease contraction and 35 examined their association with communicable disease outcomes (three examined their association with both contraction and outcomes). Fifty out of 53 reviews (94%) concluded that at least one of the behavioural risk factors studied increased the risk of contracting or experiencing worse health outcomes from a communicable disease. Across all reviews, effect sizes, where calculated, ranged from 0.83 to 8.22.

* Correspondence: m.a.bellis@bangor.ac.uk

¹Policy and International Health, World Health Organization Collaborating Centre on Investment for Health and Well-being, Public Health Wales, Wrexham, UK

²Public Health Collaborating Unit, School of Medical and Health Sciences, Bangor University, Wrexham, UK

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Conclusions: Behavioural risk factors play a significant role in the risk of contracting and experiencing more severe outcomes from communicable diseases. Prevention of communicable diseases is likely to be most successful if it involves the prevention of behavioural risk factors commonly associated with NCDs. These findings are important for understanding risks associated with communicable disease, and timely, given the COVID-19 pandemic and the need for improvements in future pandemic preparedness. Addressing behavioural risk factors should be an important part of work to build resilience against any emerging and future epidemics and pandemics.

Keywords: Infectious disease, COVID-19, Risk factors, Obesity, Smoking, Drug use, Alcohol, Prevention, Pandemic, Resilience

Background

The recent coronavirus (COVID-19) pandemic has highlighted that individuals with potentially modifiable behavioural risk factors that are commonly associated with non-communicable diseases (NCDs), such as smoking, harmful alcohol use, obesity and physical inactivity, are more likely to experience severe symptoms from COVID-19 infection [1], resulting in greater risk of hospitalisation [2]. With these behavioural risk factors often having higher prevalence in the poorest communities, COVID-19 has disproportionately impacted those already suffering the greatest risks of ill health, thereby widening health and social inequalities [3]. Indeed, due to its associations with existing health and social risk factors, COVID-19 has been referred to as a syndemic; one in which existing health and social challenges increase an individual's susceptibility to disease [4]. However, whilst addressing behavioural risk factors is routinely considered in the prevention of NCDs, their role in the contraction of communicable disease, and severity of symptoms in those who are infected, has had a lower public health prominence.

Many modifiable behavioural risk factors are highly prevalent among adults and adolescents in both higher (HICs) and lower and middle income countries (LMICs) [5, 6], with levels increasing in many LMICs (e.g. obesity, alcohol) [7, 8]. As a result, NCDs, such as cancer, respiratory disease and cardiovascular disease are the highest cause of mortality and morbidity in HICs and account for a rapidly increasing proportion of both in LMICs [9]. Across countries globally, the burden of NCDs has been found to correlate with levels of COVID-19 cases and deaths [10].

With both international commerce and tourism connecting populations globally, it is highly likely that COVID-19 is only one in a series of existing and emerging infectious diseases likely to impact, to different extents, health and well-being on a global scale [11]. Although the exact nature or source of any future epidemic or pandemic threat is speculative, behavioural risk factors have also been found to increase the risk of infection and subsequent poorer outcomes across a range of other communicable diseases [12–14]. Understanding which factors may

increase or reduce risk of contraction and severity of disease can provide important intelligence, both in increasing a population's resilience to infectious disease, and in identifying which communities and individuals may be most at risk from the spread of different types of disease. Although previous research has explored links between behavioural risk factors and individual communicable diseases, few studies have synthesised information across a wider range of communicable diseases and their relationships with behavioural risks. Indeed, such relationships may elucidate how future pandemics threats will exploit behavioural risk factors.

Intending to explore whether communicable diseases and NCDs share a common set of behavioural risk factors, the aim of this review was to provide a synthesis of existing research examining the impact of behavioural risk factors commonly associated with NCDs on the risk of people (adults or children) contracting, or experiencing more severe outcomes from, common communicable diseases. With the breadth of communicable diseases requiring limitation, the focus of this review was on diseases common to high income countries. With an intentionally wide focus on a range of communicable diseases, the review focused specifically on systematic reviews and meta-analyses, clarifying existing knowledge and highlighting gaps in evidence to inform priority areas for future research.

Methods

This review was carried out in adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. An a priori protocol was followed and prospectively registered at the National Institute for Health Research international prospective register of systematic reviews (PROSPERO) (registration number CRD42020223890). The focus of this review was limited to behavioural risk factors and communicable diseases common in HICs, regardless of the geographical location of the review. Those more specific to LMICs or certain regions of the world (e.g. tropical diseases) were considered best examined in a separate study.

Search strategy

A systematic search was performed across multiple databases through ProQuest covering the 10-year period 28th October 2010 to 28th October 2020. Preliminary scans of the literature reviews and discussion between members of the research team were used to aid selection of common behavioural risk factors and communicable diseases. Thus, alcohol use, smoking, physical inactivity, obesity, illicit drug use and poor diet were chosen as behavioural risk factors, covering some of the most common behavioural contributors to NCDs [15]. The same process identified: Tuberculosis (TB), acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV), viral hepatitis, COVID-19, severe acute respiratory syndrome (SARS), middle-east respiratory syndrome (MERS), pneumonia, influenza, and meningitis as communicable diseases (including infections and pathogens) feasible for review. These communicable diseases were broadly consistent with some of the most prevalent disease/infection categories reported in the global burden of disease study for HICs (excluding those categories predominantly affecting specific groups (e.g. maternal, neonatal) or where a component may be associated with non-infectious causes (e.g. diarrheal) [9]) and with previous outbreaks or epidemics involving HICs [16]. In addition, it was intended to include diseases that arose from both bacterial and viral pathogens, with a range of transmission types, e.g. airborne, droplet, fomite, blood-borne and contact. Combinations of search terms were developed based on these key risk factors and diseases. Search results were restricted to English language and peer reviewed systematic reviews and meta-analyses. Whilst this strategy restricted literature to that which qualified for inclusion in systematic reviews, it allowed for the inclusion of multiple behavioural risk factors and communicable diseases at the same time. The search was restricted to a 10-year period, allowing coverage of a broad range of behavioural risk factors and communicable diseases, yet limiting the literature to a manageable volume. The full search strategy is available in Supplementary file 1. Searches also included poor housing conditions as a risk factor given the impact of housing conditions on respiratory disease [17], but this study focuses specifically on behavioural risk factors.

Study selection and eligibility criteria

To identify eligible studies, the titles and abstracts of studies retrieved were screened by two reviewers, with a sample of 15% screened independently by both reviewers and achieving 98.5% agreement (SH, NJ). Discrepancies were resolved between reviewers. For full text screening, ten reviews (7%) were initially screened by three reviewers (SH, NJ, SW), with results later discussed and

discrepancies resolved. Following this, the full text screening was divided across reviewers and any reviews that were not a clear exclude/include (20%) were discussed and agreed between reviewers. This meant that, across all reviews screened by full text, 27% were discussed and agreed by more than one reviewer. Where full texts could not be accessed, authors were contacted to request the full text.

Systematic reviews and meta-analyses of observational studies (including cohort and case-control studies) that examined the association between an identified behavioural risk factor and the contraction or outcomes of an identified communicable disease (including infection or related pathogens) were included in the review. Since there are no single definitions of the selected risk factors across the literature, all reviews that focused on an identified risk factor were included regardless of the definition used in the review (definitions are provided in Tables 1 and 2 and in the results section). An aim of the review was to explore risks associated with illicit drug use in general. However, it was recognised that injection drug use can be a mechanism of transmission for some pathogens relating to included communicable diseases (e.g. HIV, HCV). Studies that focused specifically on injection drug use were therefore included alongside those focusing on drug use more generally. Studies were excluded if they: were not a systematic review or meta-analysis; did not examine the association between an selected behavioural risk factor and the contraction or outcomes of an selected communicable disease; included only selected specialist sub-populations (e.g. sex workers, prisoners), or included sub-populations relating to a risk factor (e.g. people who inject drugs) without a general population comparison; or included behavioural risk factors or communicable diseases not relevant to HICs (see above). No restrictions were made for the age of participants included. A flow chart demonstrating the selection process is presented in Fig. 1.

Data extraction and synthesis

Data were extracted by three reviewers (SH, NJ, SW) into a standardised, pre-piloted form. Each extraction was duplicated across reviewers and discrepancies resolved through discussion. Information extracted from the studies included: title, authors, abstract, behavioural risk factor(s) studied, communicable disease(s) studied (including infection or related pathogens), research question, geographical restrictions, population characteristics, number of reviews included in the systematic review or meta-analysis, main findings (including odds ratios (OR), relative risks (RR) or rate ratios where available), proposed mechanisms of association and conclusions related to identified behavioural risk factor(s) and communicable disease(s). Where information

Table 1 Results and main conclusions relating to identified risk factors from included studies: risk of contraction

Disease contracted	Ref	Definition of risk factor	Meta-analysis findings		No. of studies ^a	Conclusion ^b Effect direction
			Comparison group	Effect size (95% CI)		
Alcohol as a risk factor						
TB	[18]	Any alcohol use or higher amounts	No alcohol or lower amounts	OR 1.90 (1.63–2.23)	44	↑
	[19]	Alcohol consumption	N/A		Unclear	–
HIV	[20]	Binge drinking or alcohol misuse	N/A		2	↑
	[21]	Any alcohol use or higher amounts	No alcohol or lower amounts	RR 1.83 (1.30–2.57)	14	↑
Pneumonia	[22]	AUD	No AUD	RR 8.22 (4.85–13.95)	2	↑
	[23]	Alcohol consumption	N/A		6	↑
Illicit drug use as a risk factor						
TB	[19]	Drug abuse	–		Unclear	–
	[24]	Injection drug use	–		Unclear	↑
HIV	[20]	Injecting drugs, smoking crack cocaine	–		7	↑
	[25]	Illicit drug use	–		7	↑
HCV	[24]	Injection drug use	–		Unclear	↑
	[26]	PWID	Community based studies and blood donors	Prevalence of HCV: PWID 44.71% (37.5–52.03) Community 0.85% (0.00–3.98) Blood donors 0.44% (0.40–0.49)	46 4 211	↑
	[27]	PWID	General population	Prevalence of HCV: PWID 52.2% (46.9–57.5) General pop. 0.3% (0.2–0.4)	56 122	↑
	[28]	PWID	General population	Prevalence of HCV: PWID 53.6% (36.2–70.6) General pop. 6.2% (5.7–6.7)	15 148	↑
	[29]	PWID	–		7	↑
Obesity as a risk factor						
Influenza	[30]	Obesity and morbid obesity	–		7	↑
Pneumonia	[31]	Obesity (BMI: 30–39.9 kg/m ²)	Normal weight	CAP: RR 1.03 (CI 0.8–1.3) Influenza related: RR 1.31 (1.05–1.63) Nosocomial: RR 1.26 (0.80–1.98)	10 10 5	↑
	[32]	Overweight and obesity	Normal weight	RR 1.33 (95% CI 1.04–1.71)	13	↑
Smoking as a risk factor						
HIV	[20]	Current smoking	–		1	↑
	[33]	a) Current smoking b) Ever smoked	Never smokers	a) OR 2.17 (1.70–2.76) b) OR 2.31 (1.99–2.69)	13 13	↑
Pneumonia	[23]	Current or former smoking	–		6	↑
Second-hand smoke as a risk factor						
TB	[34]	Exposure to ETS	No exposure to ETS	TB infection (children): OR 1.9 (0.9–2.9) TB disease (children): OR 2.8 (0.9–4.8)	3 5	↑

Table 1 Results and main conclusions relating to identified risk factors from included studies: risk of contraction (Continued)

Disease contracted	Ref	Definition of risk factor	Meta-analysis findings		No. of studies ^a	Conclusion ^b Effect direction
			Comparison group	Effect size (95% CI)		
	[35]	Exposure to SHS	No exposure to SHS	TB infection (children): RR 1.19 (0.90–1.57) TB disease: RR 1.59 (1.11–2.27)	6 6	↑—
	[36]	Exposure to SHS	No exposure to SHS	TB infection: RR 1.67 (1.12–2.48) and adjusting for age/SES, RR 1.11 (0.90–1.57) TB disease: RR 1.96 (1.37–2.80) and adjusting for age/SES, RR 2.13 (1.18–3.83)	6 12	—
Pneumonia	[33]	Exposure to ECS	No exposure to ECS	Aged 65+: OR 1.64 (1.17–2.30) All ages: OR 1.13 (0.94–1.36)	2 5	↑—
IBD	[37]	Exposure to SHS	No exposure to SHS	IMD: OR 2.02 (1.52–2.69) IHD: OR 1.22 (0.93–1.62) and IHD (pre-schoolers) OR 1.46 (1.19–1.81) IPD: OR 1.21 (0.69–2.14)	16 12 9 4	↑—
Influenza Pneumonia	[38]	Lack of prolonged, moderate aerobic exercise	—		7	↑

^a Number of studies for either the meta-analysis or (for narrative reviews) the risk factor. ^b Conclusion statements are included in Supplementary file 2. Effect direction is based on conclusions: ↑ = increased risk; ↓ = decreased risk; — = no association. OR Odds ratio, RR Relative risk, TB Tuberculosis, HIV Human immunodeficiency virus, HCV Hepatitis C virus, IBD Invasive bacterial disease, IPD Invasive pneumococcal disease, IMD Invasive meningococcal disease, IHD Invasive Hib disease, CAP Community acquired pneumonia, AUD Alcohol use disorder, BMI Body mass index, SHS Second-hand smoke, ETS Environmental tobacco smoke, ECS Environmental cigarette smoke, PWID People who inject drugs

on the number of reviews included for each risk factor was not reported, the corresponding author of the paper was contacted for additional information.

Due to the variety of different communicable diseases, risk factor definitions, outcome measures, and methods of reporting in the included studies, as well as the challenges of conducting meta-analysis for observational studies [71], findings were not combined statistically through meta-analysis. Instead, a narrative synthesis of the findings was constructed [72], and effect size ranges reported for each behavioural risk factor. Key information that would have enabled calculation of a common effect size was often not available. To calculate these effect size ranges, it was assumed that ORs, RRs and rate ratios were approximately equivalent, a method suggested for umbrella reviews in these circumstances [73]. In addition, where studies reported reduced risk of a communicable disease with a health behaviour (e.g. physical activity, no alcohol drinking), an inverse OR (1/OR) for the corresponding risk behaviour was reported. Findings were structured according to the identified behavioural risk factors and their association with a) contraction of the identified communicable diseases, and b) experiencing more severe outcomes from these communicable diseases. Some study conclusions were amended for readability, to aid understanding. Further, where study conclusions were not relevant to the current research question, information was extracted

from results sections and amended for readability (see Supplementary file 2).

Methodological quality of studies

The methodological quality of included studies was assessed using the Overview Quality Assessment Questionnaire (OQAQ); a frequently used, validated tool for assessing the methodological quality of systematic reviews [74]. Methodological quality assessment was carried out by three researchers (NJ, SH, SW), with any discrepancies resolved through discussion. Assessment ratings are available in Supplementary file 2.

Results

The database search yielded 1806 citations, of which 53 were included (Fig. 1). Research relating to the following communicable diseases (including infection and pathogens) was identified: TB, HIV, hepatitis C virus (HCV), hepatitis B virus (HBV), invasive bacterial disease (IBD), pneumonia, influenza, and COVID-19. No studies relating to SARS, MERS or meningitis were identified. Thirty-six of the identified systematic reviews also conducted meta-analyses. Reviews used a range of definitions of behavioural risk factors (e.g. current or former smoker, any alcohol use or heavy alcohol use). All definitions were included in the synthesis, and are presented for clarity in each section of the results and in the results tables (Tables 1 and 2). Eighteen reviews examined the

Table 2 Results and main conclusions relating to identified risk factors from included studies: risk of more severe outcomes

Disease	Ref	Definition of more severe outcomes	Definition of risk factor (where recorded)	Meta-analysis (MA) findings		No. of studies ^a	Conclusion ^b Effect direction
				Comparison group	Effect size (95% CI)		
Alcohol as a risk factor							
TB	[39]	Death	Alcoholism	–		Unclear	↑
	[40]	Treatment default, failure or death	Alcohol misuse	No alcohol misuse	RR 1.45 (1.21–1.74)	15	↑
	[41]	MDR TB	Alcohol use	–		8	↑
	[19]	Poor outcomes	Alcohol use	–		Unclear	–
	[42]	Relapse after treatment	Alcoholism	–		1	↑
	[43]	Unsuccessful treatment	Alcohol use	No alcohol use	OR 2.0 (1.67–2.50)	9	↑
	[44]	Death, treatment failure, lost to follow up	Alcohol use	No or low alcohol use	DS-TB OR 1.99 (1.57–2.51) MDR-TB OR 2.00 (1.73–2.32)	25 18	↑
HIV	[45]	Poor treatment outcomes	Alcohol use disorders	–		10	↑
	[46]	Viral non-suppression	Alcohol use	No alcohol use	OR 2.47 (1.58–3.87)	6	↑
	[47]	HIV progression, survival	Alcohol use	–		17	~
HCV	[48]	No spontaneous clearance	Current/history of excess use	No history of excess use	OR 1.49 (1.05–2.13)	5	↑
	[49]	No achievement of SVR	Alcohol use	–		10	↑
Illicit drug use a risk factor							
TB	[39]	Death	Injection drug use	–		Unclear	↑
	[41]	MDR-TB	Drug abuse	–		7	↑
	[19]	Poor outcomes	Drug abuse	–		Unclear	–
HIV	[50]	AIDS-related mortality	Regular/problem cocaine use	General pop.	SMR 23.12 (11.30–47.31)	6	↑
HCV	[48]	No spontaneous clearance	History of injection drug use	Non-injecting drug use	OR 1.69 (1.08–2.70)	7	↑
	[51]	Reinfection with HCV	Recent drug use	Receiving OAT with no recent drug use	OAT: aRR 3.50 (1.62–7.53) No OAT: aRR 3.96 (1.82–8.59)	21 15	↑
	[52]	No achievement of SVR	Recent People who inject drugs (PWID)	Non recent PWID	RR 1.01 (0.95–1.08)	10	–
HBV/HDV	[53]	Infection with HDV (among those with HBV)	Intravenous drug users (IVDUs)	Mixed population, no risk factors	HDV seroprevalence: IVDUs 37.57% (29.30–46.20) Mixed pop. 10.58% (9.14–12.11)	44 177	↑
Obesity as a risk factor							
Influenza	[54]	ICU admission or death	a) Obesity, BMI ≥ 30 kg/m ² b) Morbid obesity ≥ 40 kg/m ²	a) Not obese b) Not morbidly obese	a) OR 2.14 (0.92–4.99) b) OR 2.01 (1.29–3.14)	5 5	↑
	[30]	Higher level of healthcare	Obesity and morbid obesity	–		7	↑
	[55]	Death	Obesity BMI > 30 kg/m ²	Not obese	OR 2.74 (1.56–4.80)	33	↑
	[56]	a) Hospital admission	Obesity BMI > 30 kg/m ²	Not obese	a) RR 1.82 (1.48–2.24)	15	↑

Table 2 Results and main conclusions relating to identified risk factors from included studies: risk of more severe outcomes (Continued)

Disease	Ref	Definition of more severe outcomes	Definition of risk factor (where recorded)	Meta-analysis (MA) findings		No. of studies ^a	Conclusion ^b Effect direction
				Comparison group	Effect size (95% CI)		
		b) ICU admission or death			b) Adults: RR 1.40 (1.01–1.95), Children: RR 0.91 (0.47–1.74)	24 8	
COVID-19	[57]	Poor outcomes	Obesity			9	↑—
	[58]	ICU admission, IMV or death	Obesity	Non-obese	RR 1.40 (0.91–2.17)	3	↑
	[59]	Worse outcomes	Obesity or overweight			20	↑
	[60]	a) ICU admission	Obesity (BMI Asians > 25 kg	Non-obese	a) OR 1.21 (1.00–1.46)	6	↑
		b) IMV	/m ² , Caucasians > 30 kg/m ²)		b) OR 2.05 (1.16–3.64)	5	
Pneumonia	[32]	Mortality	Overweight and obesity	Normal weight	RR 0.83 (0.77–0.91)	10	↓
Smoking as a risk factor							
TB	[39]	Death	Smoking			Unclear	–
	[41]	DR TB	Smoking			13	↑
	[19]	Poor outcomes	Smoking			Unclear	↑
	[43]	Unsuccessful treatment	Smoking			16	↑
	[40]	Treatment default, failure or death	Smoking	Non-smokers	RR 0.94 (0.75–1.19)	11	–
	[61]	a) Unfavourable outcomes	Current cigarette smoking	Non-smokers	a) OR 1.23 (1.14–1.33)	8	↑
		b) Delayed smear/culture conversion			b) OR 1.55 (1.04–2.07)	5	
	[42]	Relapse after treatment	Smoking			2	↑
Influenza	[62]	DR TB	Current/past smoking	Non-smokers	OR 1.57 (1.33–1.86)	33	↑
	[56]	a) Hospital admission	Tobacco smoking	Non-tobacco smokers	a) RR 1.24 (1.07–1.43)	10	↑
		b) ICU admission or death			b) RR 1.46 (1.25–1.69)	30	
COVID-19	[63]	Adverse outcomes	Current smoking	Non-current smokers	OR 1.53 (1.06–2.20)	18	↑
	[64]	ARDS, ICU admission or death	Smoking	Non-smokers	OR 1.54 (1.07–2.22)	5	↑
	[65]	ICU, severe oxygenation, IMV, death	Current smoking	Past/never smokers	RR 1.45 (1.03–2.04)	2	↑
	[66]	ICU admission or death	a) History of smoking	Non-smokers	a) OR 2.17 (1.37–3.46)	16	↑
			b) Current smoking		b) OR 1.51 (1.12–2.05)	10	
	[67]	ICU, IMV or death	Active smoking	Non-smokers	All studies OR 1.98 (1.29–3.05)	7	↑—
					One removed OR 1.55 (0.83–2.87)	6	
	[68]	Worsening of symptoms, ICU, death	a) Current smoking	Non-smokers	a) OR 1.98 (1.16–3.39)	13	↑
		b) Former smoking		b) OR 3.46 (2.46–4.85)	4		


Table 2 Results and main conclusions relating to identified risk factors from included studies: risk of more severe outcomes (Continued)

Disease	Ref	Definition of more severe outcomes	Definition of risk factor (where recorded)	Meta-analysis (MA) findings		No. of studies ^a	Conclusion ^b Effect direction
				Comparison group	Effect size (95% CI)		
Second-hand smoke as a risk factor							
Pneumonia	[69]	Death from ALRIs (incl. pneumonia)	SHS exposure	No SHS exposure	(Children) OR 1.52 (1.20–1.93)	8	↑
Poor diet as a risk factor							
HIV	[70]	HIV progression, mortality	Vit.D deficiency/insufficiency			10	↑
HCV	[49]	No achievement of SVR	Poor quality diet			2	–

^a Number of studies for either the meta-analysis or (for narrative reviews) the risk factor. ^b Conclusion statements are included in Supplementary file 2. Effect direction is based on conclusions: ↑ = increased risk; ↓ = decreased risk; — = no association; ~ = variable results. OR Odds ratio, RR Relative risk, aRR Adjusted rate ratio, SMR Standardised mortality ratio, TB Tuberculosis, DR-TB Drug-resistant tuberculosis, MDR-TB Multi-drug resistant tuberculosis, DS-TB Drug-susceptible tuberculosis, HIV Human immunodeficiency virus, AIDS Acquired immunodeficiency syndrome, HCV Hepatitis C virus, HBV Hepatitis B virus, HDV Hepatitis D virus, ARDS Acute respiratory distress syndrome, ARLI Acute lower respiratory infection, PWID People who inject drugs, IVDU Intravenous drug user, SHS Second-hand smoke, BMI Body mass index, SVR Sustained virological response, ICU Intensive care unit, IMV Invasive mechanical ventilation, OAT Opioid agonist therapy

association between behavioural risk factors and the contraction of a communicable disease only, 32 reviews examined the association between behavioural risk factors and the outcomes from communicable diseases only, and three reviews examined associations with both

contraction of and outcomes from communicable diseases. Characteristics of all included reviews and their conclusions can be found in Supplementary file 2. No systematic review had extensive or major flaws, with most reviews having only minimal or minor flaws



(Supplementary file 2). Consequently, no reviews were excluded based on methodological quality. A breakdown of reviews by disease and risk factors is provided in Supplementary file 3.

Behavioural risk factors for communicable diseases

Overall, 50 out of 53 reviews (94%) concluded that at least one of the behavioural risk factors studied increased the risk of contracting or having more severe outcomes of a communicable disease. Across all reviews, effect sizes, where calculated, ranged from 0.83 to 8.22 (Figs. 2 and 3; Tables 1 and 2). Nineteen out of 21 reviews (90%) concluded that at least one of the behavioural risk factors studied increased the risk of contracting a communicable disease (Table 1). Across all contraction reviews, effect sizes, where calculated, ranged from 1.03 to 8.22 (Fig. 2). Thirty-two out of 35 reviews (91%) concluded that at least one of the behavioural risk factors studied increased the likelihood of having more severe outcomes from a communicable disease (Table 2). Across all outcome reviews, effect sizes, where calculated, ranged from 0.83 to 3.96 (Fig. 3).

Alcohol as a risk factor

Seventeen reviews included alcohol as a risk factor for a communicable disease, with a range of definitions used: any alcohol consumption [19, 23, 41, 43, 44, 46, 47, 49]; any alcohol use or higher amounts [18, 21]; binge drinking or alcohol misuse [20]; alcohol misuse [40]; alcohol use disorder (AUD) [22, 45]; alcoholism [39, 42]; or current/history of excess use [48]. The majority of reviews reported an increased risk of contraction (5/6 reviews; Table 1) and more severe outcomes (10/12 reviews; Table 2). Across all alcohol reviews, effect sizes, where calculated, ranged from 1.83–8.22 for contraction

(Fig. 2) and 1.45–2.47 for severe outcomes (Fig. 3). Alcohol use (any use, higher amounts, binge drinking or AUD) was reported to increase the risk of contracting TB [18], HIV [20], pneumonia [21, 22] and invasive pneumococcal diseases (IPD) [23]. One review did not draw a conclusion, but reported mixed findings for the association between alcohol consumption and contraction of TB [19]. Alcohol use (any use, misuse, current/history of excess use, alcoholism or AUD) was reported to increase the risk of having more severe outcomes from TB [39–44], HIV [45, 46], and HCV [48, 49]. One review reported mixed findings and made no clear conclusion about the association of alcohol consumption and TB outcomes [19], and one review reported variable results among studies examining the association between alcohol consumption and the progression of HIV [47].

Illicit drug use as a risk factor

Fifteen reviews examined the association between illicit drug use and communicable disease contraction or outcomes, with a wide range of definitions used: drug abuse [19, 41]; illicit drug use [25]; regular/problem cocaine use [50]; recent drug use [51]; and injection drug use [20, 24, 26–29, 39, 48, 52, 53]. The majority of reviews reported an increased risk of contraction (8/9 reviews; Table 1) and more severe outcomes (6/8 reviews; Table 2). Across all drug use reviews, effect sizes, where calculated (for more severe outcomes only), ranged from 1.01–3.96 (Fig. 3). Both injection drug use and illicit drug use were reported to increase the risk of contracting TB [24] and HIV [20, 24, 25], whilst the prevalence of HCV was found to be higher among people who inject drugs (PWID) compared to general population or community groups [26–29]. One review did not draw a conclusion but reported mixed findings for the




Fig. 2 Forest plot of meta-analysis effect sizes: contraction of a communicable disease. Effect sizes refer to odds ratios and relative risks, see Table 1 for more information. CAP = community acquired pneumonia; TB = tuberculosis; IBD = invasive bacterial disease




Fig. 3 Forest plot of meta-analysis effect sizes: more severe communicable disease outcomes. Effect sizes refer to odds ratios, relative risks and rate ratios, see Table 2 for more information. MDR = multi-drug resistant; TB = tuberculosis; DS = drug-susceptible; HIV = human immunodeficiency virus; HCV = hepatitis C virus; ICU = intensive care unit; IMV = invasive mechanical ventilation; OAT = opioid agonist therapy

association between drug abuse and TB contraction [19]. Both injecting drug use and drug use/abuse were reported to increase the risk of having more severe outcomes from TB [39, 41], HIV [50] and HCV [48, 51]. Furthermore, among those with HBV, the prevalence of hepatitis D (HDV; co-infection with HDV is considered a more severe form of viral hepatitis) was substantially higher for PWID compared to a mixed population with no risk factors [53]. One review did not draw a conclusion but reported mixed findings for the association between drug abuse and TB outcomes [19], and one review concluded that treatment outcomes for HCV were similar between people who currently were and were not injecting drugs [52].

Physical inactivity as a risk factor

One systematic review was identified examining the association between physical activity and communicable disease contraction or outcomes. This study reported an association between increased prolonged, moderate aerobic exercise and reduced influenza-related mortality, and improved immunocompetence [38].

Obesity as a risk factor

Ten reviews focused on the relationship between obesity [30, 31, 54–58, 60], or overweight and obesity [32, 59], and communicable disease risk. The majority of reviews reported an increased risk of contraction (3/3 reviews; Table 1) and more severe outcomes (8/9 reviews; Table 2). Across all obesity reviews, effect sizes, where calculated, ranged from 1.03–1.33 for contraction (Fig. 2) and 0.83–2.74 for severe outcomes (Fig. 3). Obesity was reported to increase the risk of contracting influenza [30] and pneumonia [31, 32]. Obesity was reported to

increase the risk of having more severe outcomes from influenza [30, 54–56] and COVID-19 [58–60]. One review concluded that most studies showed some degree of association between higher body mass index (BMI) and a worse clinical presentation of COVID-19 and the need for hospitalisation. This review suggested that obesity seemed to predict poor clinical evolution in patients with COVID-19, but that studies in the review had limited methodological quality [57]. However, one review, which concluded that obesity increased the risk of contracting pneumonia, also found that obese individuals had a lower mortality risk from pneumonia [32].

Smoking as a risk factor

Eighteen reviews examined the association between smoking (current, past or both) and communicable disease contraction or outcomes. The majority of reviews reported some evidence of an increased risk of contraction (3/3 reviews; Table 1) and more severe outcomes (13/15 reviews; Table 2). Across all smoking reviews, effect sizes, where calculated, ranged from 2.17–2.31 for contraction (Fig. 2) and 0.94–3.46 for severe outcomes (Fig. 3). Smoking was reported to increase the risk of contracting HIV [20], pneumonia [33] and invasive pneumococcal disease (IPD) [23]. Further, smoking was reported to increase the risk of having more severe outcomes from TB [19, 41–43, 61, 62], influenza [56], and COVID-19 [63–66, 68]. Two reviews reported no associations between smoking and more severe outcomes from communicable diseases, including death from TB [39] and TB treatment outcomes [40]. One review reported that active smoking may increase the risk of severe COVID-19, but found the result was heavily influenced by one study [67].

Second-hand smoke as a risk factor

Six reviews focused on second-hand smoke as a risk factor for a communicable disease. The majority of reviews reported some evidence of an increased risk of contraction (4/5 reviews; Table 1) and more severe outcomes (1/1 review; Table 2). Across all second-hand smoking reviews, effect sizes, where calculated, ranged from 1.11 to 2.80 for contraction (Fig. 2), and the one effect size calculated for severe outcomes was 1.52 (Fig. 3). One review suggested that second-hand smoke exposure increased the risk of TB infection and disease [34]. The remaining four reviews reported at least some evidence of second-hand smoke exposure increasing the risk of contracting a communicable disease, including TB [35, 36], pneumonia (among those aged 65+ only) [33], and IBD (invasive meningococcal disease [IMD] only) [37]. Second-hand smoke exposure was reported to increase the risk of severe outcomes from acute lower respiratory infections (ALRIs), including pneumonia [69].

Poor diet as a risk factor

Only two reviews were identified that examined the association between poor diet and communicable disease outcomes, and no reviews examining the association between poor diet and communicable disease contraction were identified. One review found that vitamin D status may influence the course of HIV disease [70]. The second review reported that a high intake of polyunsaturated fatty acids was associated with non-response to HCV antiviral therapy [49].

Discussion

The key finding of this systematic review is that behavioural risk factors play a significant role in the risk of contracting, and having more severe outcomes from, common communicable diseases. To the authors' knowledge, this is the first time that a review has brought together studies exploring the impact of behavioural risk factors on a range of communicable diseases. Whilst the focus on selected communicable diseases and use of systematic reviews has led to inevitable gaps, the findings nevertheless provide strong evidence that both NCDs and communicable diseases share a common set of behavioural risk factors. This work indicates that the prevention of communicable disease is likely to be most successful if it involves the prevention of behavioural risk factors. These findings are timely, in light of the COVID-19 pandemic, and highlight potential additional benefits of addressing behavioural risk factors ahead of any future epidemics or pandemics. While the specific diseases that may be involved can only be speculated, they are likely to share at least some characteristics with diseases in this review.

Although this review has not examined the mechanisms connecting behavioural risk factors and communicable diseases, there are likely to be multiple mechanisms. Behavioural factors, such as alcohol use, smoking, obesity, and illicit drug use, are well documented to impair the immune system. For instance, smoking is known to influence both innate and adaptive immunity [75]. Impairments to the immune system can make individuals more susceptible to communicable diseases and less able to control or recover from infection, leading to worse outcomes [76–81]. Use of alcohol/drugs may also reduce the efficacy of treatment for communicable diseases [82]. The presence of comorbidities, such as diabetes and cardiovascular disease, in individuals with behavioural risk factors has also been implicated in the increased risk of communicable diseases [83, 84]. However, behavioural risk factors, such as obesity, are also reported to independently influence communicable diseases, after adjusting for comorbidities [55]. Behavioural mechanisms may also be important, particularly for alcohol and drug use, which may reduce risk perception [78], interfere with the uptake of services, or lead to poorer treatment adherence [85]. Additionally, behavioural risk factors may be likely to appear in combination, for example combined alcohol use and smoking [86], to further increase influences on communicable diseases. Furthermore, behaviours associated with drug use, such as injecting drugs, have a high efficiency of transmission of communicable diseases and reinfection with communicable diseases [87]. Having a communicable disease could also lead to the presence of behavioural risk factors (e.g. alcohol may be used as a way of coping with the emotional distress of diseases such as HIV and HCV [88]). Finally, there may be social mechanisms, such as the social marginalisation of heavy drinkers that affects health service use or treatment [89], or social issues such as homelessness, incarceration and poverty, which may increase the risk of both behavioural risk factors and communicable diseases [90, 91]. It is likely that there are multiple ways in which these different physiological, behavioural and social factors come together to affect the likelihood of transmission and severity of communicable disease, which require further investigation.

With behavioural risk factors influencing the contraction and severity of communicable diseases, their prevention is likely to play a role in addressing future communicable disease burden, potentially through improvements in the immune system, bodily functioning and risk behaviours. As the recent COVID-19 pandemic has highlighted, their prevention is also likely to impact on communicable disease burden through the potential reduction of NCDs commonly associated with behavioural risk factors, which can also alter immune system

function [92] and increase the risk of communicable disease complications and death [10, 93]. The review findings are important in understanding communicable disease risk, and timely, in light of COVID-19. They suggest that improvements in the prevention of behavioural risk factors may serve to reduce the negative impacts of future epidemics or pandemics, building resilience and helping to address the pressing need for greater investment in pandemic preparedness [94]. Indeed, COVID-19 should not only be a reminder that good communicable disease control is necessary, but that the more successful we are in addressing behavioural risk factors, the better we will also be at reducing the burden of communicable disease, including future epidemics or pandemics. The finding that both communicable diseases and NCDs share a common set of behavioural risk factors also lends support for a more holistic understanding of these two disease categories. For instance, research suggests that NCDs and communicable diseases can interact; whilst NCDs can increase the risk and severity of communicable diseases (e.g. individuals with diabetes, hypertension and respiratory illnesses are more likely to be affected by COVID-19 [95]), at least some diseases previously considered NCDs are now known to have an infectious origin (e.g. HBV is a cause of hepatocellular carcinoma [96]).

Although the focus of this review is on HICs, findings will be of importance to LMICs, which often experience a much higher burden of communicable disease [9] and where, for many countries, the prevalence of behavioural risk factors is increasing [7, 8]. Due to ageing populations, the negative impacts of globalisation, and ill-equipped health systems, these countries are also facing a rapidly growing burden of NCDs [97–99], which may reduce resistance to infection, increase communicable disease complications, or interfere with its treatment [100, 101]. In the current global society, any negative effects of rising behavioural risk factors and related NCDs on communicable disease transmission have the potential to affect not only LMICs, but health and well-being globally.

Across both HICs and LMICs, behavioural risk factors and related NCDs are known to cluster in disadvantaged populations [97, 102–104], with poverty contributing to behavioural risk factors and NCDs, and vice versa [97]. Disadvantaged communities are more likely, therefore, to experience dual burdens of NCDs and communicable disease, contributing to social and economic health inequalities. In the UK for instance, people living in the most disadvantaged communities have been over twice as likely to die from COVID-19 as those in the least disadvantaged areas [105]. Preventing behavioural risk factors, particularly among disadvantaged populations, is likely to play an important role in reducing future global

and national health inequalities, as well as the unequal burden of future pandemics.

There are some limitations to this work. The wide-ranging nature of the research allowed for a broad view of the links between behavioural risk factors and communicable diseases. However, this did not allow for the exploration of causal pathways of specific associations. Further research exploring these pathways would aid understanding and inform prevention. The use of systematic reviews to achieve a broader range of information also meant that newer empirical research may have been missed, only more widely researched topics for which there is enough information to conduct a systematic review would have been included, and more in-depth information such as potential interactions between risk factors could not be included. With no single definitions of behavioural risk factors agreed across the literature, it was not possible to standardise the definitions of risk factors in this review, meaning that there was often variation in the definitions included in each risk factor category, hampering discussion of relationships. Low socio-economic status (SES) and other factors associated with low SES, such as poor housing, are likely to be an important element in the link between behavioural risk factors and communicable diseases, although little is currently known about the influence of low SES and associated factors. It was not possible to explore the role of low SES within the review since many of the reviews included did not explore low SES in their analyses. Many of the included studies are global syntheses, however, the relationships between behavioural risk factors and communicable diseases may vary between countries. Only papers written in English were included, meaning that research in other languages may have been missed. Finally, conclusions should be considered with publication bias in mind; papers are more likely to be published if they reveal significant effects rather than null findings [106], so those reporting that behavioural risk factors are associated with communicable diseases are more likely to be identified.

This work identified several gaps in the current systematic review literature relating to specific behavioural risk factors and common communicable diseases, including studies examining the association of physical inactivity and poor dietary habits with communicable diseases, which warrant urgent further exploration. For instance, recently published literature has indeed highlighted the important role of physical inactivity in severe COVID-19 risk [2, 107]. Due to the study being limited to systematic reviews only, a comprehensive comparison of behavioural risk factors across different disease types could not be provided; although future reviews could provide such comparisons. However, it was noted that reviews examining the association of communicable diseases with alcohol

and illicit drug use largely focused on TB, HIV and hepatitis, whereas reviews examining association with obesity largely focused on pneumonia, influenza and COVID-19 (see Supplementary file 3). Further research understanding the more intricate ways in which individual behavioural risk factors are linked to specific types of disease, and the mechanisms by which they are linked, would provide a valuable framework for understanding how current and future communicable diseases may affect different population groups. Finally, findings highlight an opportunity for future research to examine the efficacy of behavioural risk factor prevention efforts in reducing communicable disease burden.

Conclusions

Behavioural risk factors play a significant role in the risk of contracting, and having more severe outcomes from, common communicable diseases. These risk factors are largely modifiable or preventable. Prevention of communicable diseases is likely to be most successful if it involves the prevention of behavioural risk factors that are commonly associated with NCDs, particularly among disadvantaged populations. These findings are important for understanding risks associated with communicable disease, and timely, given the current COVID-19 pandemic and need for improvements in future pandemic preparedness. Addressing behavioural risk factors should be an important part of work to build resilience against any emerging and future epidemics and pandemics. Furthermore, the pandemic can offer a timely, teachable moment for the public on how improvements to general health, through addressing risk behaviours commonly associated with NCDs, may help protect them from infections like COVID-19 in the future.

Abbreviations

AIDS: Acquired immune deficiency syndrome; ALRI: Acute lower respiratory infections; BMI: Body mass index; HCV: Hepatitis C virus; HDV: Hepatitis D virus; HIC: High-income country; HIV: Human immunodeficiency virus; IBD: Invasive bacterial disease; IPD: Invasive pneumococcal disease; IMD: Invasive meningococcal disease; LMIC: Lower-middle income country; MERS: Middle east respiratory syndrome; NCD: Non-communicable disease; OR: Odds ratio; OQAQ: Overview quality assessment questionnaire; PRISMA: Preferred reporting items for systematic reviews and meta-analyses; PROSPERO: International prospective register of systematic reviews; RR: Relative risk; SARS: Severe acute respiratory syndrome; TB: Tuberculosis

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12889-021-12148-y>.

Additional file 1.

Additional file 2.

Additional file 3.

Acknowledgements

We would like to thank Rebecca Hill and Nel Griffith, Public Health Wales, for their assistance in reviewing this manuscript.

Authors' contributions

MB and KH contributed to the conception, design and direction of the project. SW managed the project with SH and NJ. NJ and SH undertook the literature searches and conducted the initial data screening. NJ, SH and SW conducted the full text screening, data extraction and quality assessment. SH synthesised the findings. AJ and all other authors contributed to the manuscript write up / revisions. All authors read and approved the final manuscript.

Funding

This project was funded by Public Health Wales.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Policy and International Health, World Health Organization Collaborating Centre on Investment for Health and Well-being, Public Health Wales, Wrexham, UK. ²Public Health Collaborating Unit, School of Medical and Health Sciences, Bangor University, Wrexham, UK. ³Institute for Applied Human Physiology, School of Human and Behavioural Sciences, Bangor University, Bangor, UK. ⁴Health Protection and Screening Services, Public Health Wales, Cardiff, UK.

Received: 7 October 2021 Accepted: 22 October 2021

Published online: 17 November 2021

References

- World Health Organization and the United Nations Development Programme. Responding to non-communicable diseases during and beyond the COVID-19 pandemic. 2020. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Non-communicable_diseases-Evidence-2020.1. Accessed 24 June 2021.
- Hamer M, Kivimäki M, Gale CR, Batty GD. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: a community-based cohort study of 387,109 adults in UK. *Brain Behav Immun*. 2020;87:184–7. <https://doi.org/10.1016/j.bbi.2020.05.059>.
- Bambra C, Riordan R, Ford J, Matthews F. The COVID-19 pandemic and health inequalities. *J Epidemiol Community Health*. 2020;74(11):964–8. <https://doi.org/10.1136/jech-2020-214401>.
- Horton R. Offline: COVID-19 is not a pandemic. *Lancet*. 2020;396(10255):874. [https://doi.org/10.1016/S0140-6736\(20\)32000-6](https://doi.org/10.1016/S0140-6736(20)32000-6).
- World Health Organization. The Global Health Observatory. Available from: <https://www.who.int/data/gho>. Accessed 8 Nov 2021.
- Global Burden of Disease Collaborative Network. GBD Results Tool. 2021. Available from: <http://ghdx.healthdata.org/gbd-results-tool>. Accessed 24 June 2021.
- Uddin R, Lee E-Y, Khan SR, Tremblay MS, Khan A. Clustering of lifestyle risk factors for non-communicable diseases in 304,779 adolescents from 89 countries: a global perspective. *Prev Med An Int J Devoted to Pract Theory*. 2020;131:8. <https://doi.org/10.1016/j.jpmed.2019.105955>.
- Ford ND, Patel SA, Narayan KMV. Obesity in low- and middle-income countries: burden, drivers, and emerging challenges. *Annu Rev Public Health*. 2017;38(1):145–64. <https://doi.org/10.1146/annurev-publhealth-031816-044604>.
- World Health Organization. Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018.
- Azarpazhooh MR, Morovatdar N, Avan A, Phan TG, Divani AA, Yassi N, et al. COVID-19 pandemic and burden of non-communicable diseases: an

- ecological study on data of 185 countries. *J Stroke Cerebrovasc Dis.* 2020; 29(9):1–9. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105089>.
11. Bloom DE, Cadarette D. Infectious disease threats in the twenty-first century: strengthening the global response. *Front Immunol.* 2019;10:549. <https://doi.org/10.3389/fimmu.2019.00549>.
 12. Hamer M, O'Donovan G, Stamatakis E. Lifestyle risk factors, obesity and infectious disease mortality in the general population: linkage study of 97,844 adults from England and Scotland. *Prev Med (Baltim).* 2019;123:65–70. <https://doi.org/10.1016/j.ypmed.2019.03.002>.
 13. Baik I, Curhan GC, Rimm EB, Bendich A, Willett WC, Fawzi WW. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. *Arch Intern Med.* 2000; 160(20):3082–8. <https://doi.org/10.1001/archinte.160.20.3082>.
 14. Creswell J, Raviglione M, Ottmani S, Migliori GB, Uplekar M, Blanc L, et al. Tuberculosis and noncommunicable diseases: neglected links and missed opportunities. *Eur Respir J.* 2011;37(5):1269–82. <https://doi.org/10.1183/09031936.00084310>.
 15. Majid E, Elio R. Behavioral and dietary risk factors for noncommunicable diseases. *N Engl J Med.* 2013;369(10):954–64. <https://doi.org/10.1056/NEJMr1203528>.
 16. World Health Organization. Disease outbreaks. 2021. Available from: <https://www.who.int/emergencies/diseases/en/>. Accessed 24 June 2021.
 17. Wimalasena NN, Chang-Richards A, Wang KI-K, Dirks KN. Housing risk factors associated with respiratory disease: a systematic review. *Int J Environ Res Public Health.* 2021;18(6):2815. <https://doi.org/10.3390/ijerph18062815>.
 18. Simou E, Britton J, Leonardi-Bee J. Alcohol consumption and risk of tuberculosis: a systematic review and meta-analysis. *Int J Tuberc Lung Dis.* 2018;22(11):1277–85. <https://doi.org/10.5588/ijtld.18.0092>.
 19. Mohidem NA, Hashim Z, Osman M, Shaharudin R, Farrah MM, Makeswaran P. Demographic, socio-economic and behavior as risk factors of tuberculosis in Malaysia: a systematic review of the literature. *Rev Environ Health.* 2018; 33(4):407–21. <https://doi.org/10.1515/reveh-2018-0026>.
 20. Rumbwere Dube BN, Marshall TP, Ryan RP, Omonijo M. Predictors of human immunodeficiency virus (HIV) infection in primary care among adults living in developed countries: a systematic review. *Syst Rev.* 2018;7(1):82. <https://doi.org/10.1186/s13643-018-0744-3>.
 21. Simou E, Britton J, Leonardi-Bee J. Alcohol and the risk of pneumonia: a systematic review and meta-analysis. *BMJ Open.* 2018;8(8):e022344. <https://doi.org/10.1136/bmjopen-2018-022344>.
 22. Samokhvalov AV, Irving HM, Rehm J. Alcohol consumption as a risk factor for pneumonia: a systematic review and meta-analysis. *Epidemiol Infect.* 2010;138(12):1789–95. <https://doi.org/10.1017/S0950268810000774>.
 23. Cruickshank HC, Jefferies JM, Clarke SC. Lifestyle risk factors for invasive pneumococcal disease: a systematic review. *BMJ Open.* 2014;4(6):e005224. <https://doi.org/10.1136/bmjopen-2014-005224>.
 24. Pimpin L, Drumright LN, Kruijshaar ME, Abubakar I, Rice B, Delpech V, et al. Tuberculosis and HIV co-infection in European Union and European economic area countries. *Eur Respir J.* 2011;38(6):1382–92. <https://doi.org/10.1183/09031936.00198410>.
 25. Zhao Y, Luo T, Tucker JD, Wong WCV. Risk factors of HIV and other sexually transmitted infections in China: a systematic review of reviews. *PLoS One.* 2015;10(10):e0140426. <https://doi.org/10.1371/journal.pone.0140426>.
 26. Goel A, Seguy N, Aggarwal R. Burden of hepatitis C virus infection in India: a systematic review and meta-analysis. *J Gastroenterol Hepatol.* 2019;34(2): 321–9. <https://doi.org/10.1111/jgh.14466>.
 27. Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: systematic review and meta-analyses. *Sci Rep.* 2018;8(1):1. <https://doi.org/10.1038/s41598-017-18296-9>.
 28. Al Kanaani Z, Mahmud S, Kouyoumjian SP, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. *R Soc Open Sci.* 2018;5(4):180257. <https://doi.org/10.1098/rsos.180257>.
 29. Fadlalla FA, Mohamoud YA, Mumtaz GR, Abu-Raddad LJ. The epidemiology of hepatitis C virus in the Maghreb region: systematic review and meta-analyses. *PLoS One.* 2015;10(3):e0121873. <https://doi.org/10.1371/journal.pone.0121873>.
 30. Falagas M, Koletsis PK, Baskouta E, Rafailidis PI, Dimopoulos G, Karageorgopoulos DE. Pandemic a(H1N1) 2009 influenza: review of the southern hemisphere experience. *Epidemiol Infect.* 2011;139(1):27–40. <https://doi.org/10.1017/S0950268810002037>.
 31. Phung DT, Wang Z, Rutherford S, Huang C, Chu C. Body mass index and risk of pneumonia: a systematic review and meta-analysis. *Obes Rev.* 2013; 14(10):839–57. <https://doi.org/10.1111/obr.12055>.
 32. Nie W, Zhang Y, Jee SH, Jung KJ, Li B, Xiu Q. Obesity survival paradox in pneumonia: a meta-analysis. *BMC Med.* 2014;12(1):61. <https://doi.org/10.1186/1741-7015-12-61>.
 33. Baskaran V, Murray RL, Hunter A, Lim WS, McKeever TM. Effect of tobacco smoking on the risk of developing community acquired pneumonia: a systematic review and meta-analysis. *PLoS One.* 2019;14(7):e0220204. <https://doi.org/10.1371/journal.pone.0220204>.
 34. Jafta N, Jeena PM, Barregard L, Naidoo RN. Childhood tuberculosis and exposure to indoor air pollution: a systematic review and meta-analysis. *Int J Tuberc Lung Dis.* 2015;19(5):596–602. <https://doi.org/10.5588/ijtld.14.0686>.
 35. Dogar OF, Pillai N, Safdar N, Shah SK, Zahid R, Siddiqi K. Second-hand smoke and the risk of tuberculosis: a systematic review and a meta-analysis. *Epidemiol Infect.* 2015;143(15):3158–72. <https://doi.org/10.1017/S0950268815001235>.
 36. Patra J, Bhatia M, Suraweera W, Morris SK, Patra C, Gupta PC, et al. Exposure to second-hand smoke and the risk of tuberculosis in children and adults: a systematic review and meta-analysis of 18 observational studies. *PLoS Med.* 2015;12(6):e1001835. <https://doi.org/10.1371/journal.pmed.1001835>.
 37. Lee C-C, Middaugh NA, Howie SRC, Ezzati M. Association of secondhand smoke exposure with pediatric invasive bacterial disease and bacterial carriage: a systematic review and meta-analysis. *PLoS Med.* 2010;7(12): e1000374. <https://doi.org/10.1371/journal.pmed.1000374>.
 38. Song Y, Ren F, Sun D, Wang M, Baker JS, István B, et al. Benefits of exercise on influenza or pneumonia in older adults: a systematic review. *Int J Environ Res Public Health.* 2020;17(8):2655. <https://doi.org/10.3390/ijerph17082655>.
 39. Waitt CJ, Squire SB. A systematic review of risk factors for death in adults during and after tuberculosis treatment. *Int J Tuberc Lung Dis.* 2011;15(7): 871–85. <https://doi.org/10.5588/ijtld.10.0352>.
 40. Samuels JP, Sood A, Campbell JR, Khan FA, Johnston JC. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. *Sci Rep.* 2018;8(1):1–13. <https://doi.org/10.1038/s41598-018-23344-z>.
 41. Rajendran M, Zaki RA, Aghamohammadi N. Contributing risk factors towards the prevalence of multidrug-resistant tuberculosis in Malaysia: a systematic review. *Tuberculosis.* 2020;122:1. <https://doi.org/10.1016/j.tube.2020.101925>.
 42. Azhar G. DOTs for TB relapse in India: a systematic review. *Lung India.* 2012; 29(2):147–53. <https://doi.org/10.4103/0970-2113.95320>.
 43. Torres NMC, Rodríguez JJQ, Andrade PSP, Arriaga MB, Netto EM. Factors predictive of the success of tuberculosis treatment: a systematic review with meta-analysis. *PLoS One.* 2019;14(12):e0226507. <https://doi.org/10.1371/journal.pone.0226507>.
 44. Ragan EJ, Kleinman MB, Sweigart B, Gnatienco N, Parry CD, Horsburgh CR, et al. The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis. *Int J Tuberc Lung Dis.* 2020;24(1):73–82. <https://doi.org/10.5588/ijtld.19.0080>.
 45. Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. *Drug Alcohol Depend.* 2010;112(3):178–93. <https://doi.org/10.1016/j.drugalcdep.2010.06.014>.
 46. Velloza J, Kemp CG, Anon FM, Ramaiya MK, Creegan E, Simoni JM. Alcohol use and antiretroviral therapy non-adherence among adults living with HIV/AIDS in sub-Saharan Africa: a systematic review and meta-analysis. *AIDS Behav.* 2020;24(6):1727–42. <https://doi.org/10.1007/s10461-019-02716-0>.
 47. Ge S, Sanchez M, Nolan M, Liu T, Savage CL. Is alcohol use associated with increased risk of developing adverse health outcomes among adults living with human immunodeficiency virus: a systematic review. *J Addict Nurs.* 2018;29(2):96–118. <https://doi.org/10.1097/JAN.0000000000000220>.
 48. Aisyah DN, Shallcross L, Hully AJ, O'Brien A, Hayward A. Assessing hepatitis C spontaneous clearance and understanding associated factors—a systematic review and meta-analysis. *J Viral Hepat.* 2018;25(6):680–98. <https://doi.org/10.1111/jvh.12866>.
 49. Sublette VA, Douglas MW, McCaffery K, George J, Perry KN. Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review. *Liver Int.* 2013;33(6):894–903. <https://doi.org/10.1111/liv.12138>.
 50. Peacock A, Tran LT, Larney S, Stockings E, Santo T, Jones H, et al. All-cause and cause-specific mortality among people with regular or problematic

- cocaine use: a systematic review and meta-analysis. *Addiction*. 2021;116(4):725–42. <https://doi.org/10.1111/add.15239>.
51. Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis. *J Hepatol*. 2020;72(4):643–57. <https://doi.org/10.1016/j.jhep.2019.11.012>.
 52. Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, et al. Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs. *Liver Int*. 2019;39(12):2244–60. <https://doi.org/10.1111/liv.14152>.
 53. Chen HY, Shen DT, Ji DZ, Han PC, Zhang WM, Ma JF, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. *Gut*. 2019;68(3):512–21. <https://doi.org/10.1136/gutjnl-2018-316601>.
 54. Fezeu L, Julia C, Henegar A, Bitu J, Hu FB, Grobbee DE, et al. Obesity is associated with higher risk of intensive care unit admission and death in influenza A (H1N1) patients: a systematic review and meta-analysis. *Obes Rev*. 2011;12(8):653–9. <https://doi.org/10.1111/j.1467-789X.2011.00864.x>.
 55. Mertz D, Kim TH, Johnstone J, Lam P-P, Science M, Kuster SP, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. *BMJ*. 2013;347(aug23 1):f5061. <https://doi.org/10.1136/bmj.f5061>.
 56. Coleman BL, Fadel SA, Fitzpatrick T, Thomas S. Risk factors for serious outcomes associated with influenza illness in high- versus low- and middle-income countries: systematic literature review and meta-analysis. *Influenza Other Respir Viruses*. 2018;12(1):22–9. <https://doi.org/10.1111/irv.12504>.
 57. Peres KC, Riera R, Martimbianco ALC, Ward LS, Cunha LL. Body Mass Index and Prognosis of COVID-19 Infection. A Systematic Review. *Front Endocrinol (Lausanne)*. 2020;11:562.
 58. de Carvalho Sales-Peres SH, de Azevedo-Silva LJ, RCS B, de Carvalho Sales-Peres M, da Sílvia Pinto AC, Santiago Junior JF. Coronavirus (SARS-CoV-2) and the risk of obesity for critically illness and ICU admitted: Meta-analysis of the epidemiological evidence. *Obes Res Clin Pract*. 2020;14(5):389–97. <https://doi.org/10.1016/j.orcp.2020.07.007>.
 59. de Siqueira JW, Almeida LG, Zica BO, Brum IB, Barceló A, de Siqueira Galil AG. Impact of obesity on hospitalizations and mortality, due to COVID-19: a systematic review. *Obes Res Clin Pract*. 2020;14(5):398–403. <https://doi.org/10.1016/j.orcp.2020.07.005>.
 60. Földi M, Farkas N, Kiss S, Zádori N, Váncsa S, Szakó L, et al. Obesity is a risk factor for developing critical condition in COVID-19 patients: a systematic review and meta-analysis. *Obes Rev*. 2020;21(10):e13095. <https://doi.org/10.1111/obr.13095>.
 61. Wang EY, Arrazola RA, Mathema B, Ahluwalia IB, Mase SR. The impact of smoking on tuberculosis treatment outcomes: a meta-analysis. *Int J Tuberc Lung Dis*. 2020;24(2):170–5. <https://doi.org/10.5588/ijtld.19.0002>.
 62. Wang M-G, Huang W-W, Wang Y, Zhang Y-X, Zhang M-M, Wu S-Q, et al. Association between tobacco smoking and drug-resistant tuberculosis. *Infect Drug Resist*. 2018;11:873–87. <https://doi.org/10.2147/IDR.S164596>.
 63. Farsalinos K, Barbouni A, Poulas K, Polosa R, Caponnetto P, Niaura R, et al. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. *Ther Adv Chronic Dis*. 2020;11:1–14. <https://doi.org/10.1177/2040622320935765>.
 64. Del Sole F, Farcomeni A, Loffredo L, Carnevale R, Menichelli D, Vicario T, et al. Features of severe COVID-19: a systematic review and meta-analysis. *Eur J Clin Investig*. 2020;50(10):1–7. <https://doi.org/10.1111/eci.13378>.
 65. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almeahmadi M, Alqahtani AS, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. *PLoS One*. 2020;15(5):e0233147. <https://doi.org/10.1371/journal.pone.0233147>.
 66. Gülsen A, Yigitbas BA, Uslu B, Drömann D, Kilinc O. The effect of smoking on COVID-19 symptom severity: systematic review and meta-analysis. *Pulm Med*. 2020;2020:7590207–11. <https://doi.org/10.1155/2020/7590207>.
 67. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID-19: a systematic review and meta-analysis. *J Med Virol*. 2020;92(10):1915–21. <https://doi.org/10.1002/jmv.25889>.
 68. Sanchez-Ramirez DC, Mackey D. Underlying respiratory diseases, specifically COPD, and smoking are associated with severe COVID-19 outcomes: a systematic review and meta-analysis. *Respir Med*. 2020;171:106096. <https://doi.org/10.1016/j.rmed.2020.106096>.
 69. Sonego M, Pellegrin MC, Becker G, Lazzerini M. Risk factors for mortality from acute lower respiratory infections (ALRI) in children under five years of age in low and middle-income countries: a systematic review and meta-analysis of observational studies. *PLoS One*. 2015;10(1):17. <https://doi.org/10.1371/journal.pone.0116380>.
 70. Giusti A, Penco G, Pioli G. Vitamin D deficiency in HIV-infected patients: a systematic review. *Nutr Diet Suppl*. 2011;3:101–11. <https://doi.org/10.2147/NDS.S6921>.
 71. Metelli S, Chaimani A. Challenges in meta-analyses with observational studies. *Evid Based Ment Heal*. 2020;23(2):83–7 Available from: <http://ebmh.bmj.com/content/23/2/83.abstract>.
 72. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic Reviews. A Product from the ESRC Methods Programme. Version 1. 2006. Available from: <https://www.lancaster.ac.uk/media/lancaster-university/content-assets/documents/fhm/dhr/chir/NSsynthesisguidanceVersion1-April2006.pdf>. Accessed 24 June 2021.
 73. Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. *Evid Based Ment Health*. 2018;21(3):95–100. <https://doi.org/10.1136/ebmental-2018-300014>.
 74. Pussegoda K, Turner L, Garrity C, Mayhew A, Skidmore B, Stevens A, et al. Identifying approaches for assessing methodological and reporting quality of systematic reviews: a descriptive study. *Syst Rev*. 2017;6(1):117. <https://doi.org/10.1186/s13643-017-0507-6>.
 75. Qiu F, Liang C-L, Liu H, Zeng Y-Q, Hou S, Huang S, et al. Impacts of cigarette smoking on immune responsiveness: up and down or upside down? *Oncotarget*. 2017;8(1):268–84. <https://doi.org/10.18632/oncotarget.13613>.
 76. Díaz LE, Montero A, González-Gross M, Vallejo AI, Romeo J, Marcos A. Influence of alcohol consumption on immunological status: a review. *Eur J Clin Nutr*. 2002;56(S3):S50–3. <https://doi.org/10.1038/sj.ejcn.1601486>.
 77. Sattar N, McInnes IB, McMurray JJV. Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms. *Circulation*. 2020;142(1):4–6. <https://doi.org/10.1161/CIRCULATIONAHA.120.047659>.
 78. Andreasson S, Chikritzhs T, Dangardt F, Holder H, Naimi T, Sherk A, et al. Alcohol and society 2021: alcohol and the coronavirus pandemic: individual, societal and policy perspectives. Stockholm: Medicine, SIGHT, Movendi International & IOGT-NTO; 2021.
 79. Trivedi GY, Saboo B. The risk factors for immune system impairment and the need for lifestyle changes. *J Soc Heal Diabetes*. 2020;8(01):025–8. <https://doi.org/10.1055/s-0040-1715778>.
 80. Pacifici R, Zuccaro P, Pichini S, Roset PN, Poudevida S, Farré M, et al. Modulation of the immune system in cannabis users. *JAMA*. 2003;289(15):1929–31. <https://doi.org/10.1001/jama.289.15.1929-a>.
 81. Friedman H, Eisenstein TK. Neurological basis of drug dependence and its effects on the immune system. *J Neuroimmunol*. 2004;147(1–2):106–8. <https://doi.org/10.1016/j.jneuroim.2003.10.022>.
 82. Pandrea I, Happel KI, Amedee AM, Bagby GJ, Nelson S. Alcohol's role in HIV transmission and disease progression. *Alcohol Res Heal*. 2010;33:203–18.
 83. Vas P, Hopkins D, Feher M, Rubino F, Whyte M. Diabetes, obesity and COVID-19: a complex interplay. *Diabetes Obes Metab*. 2020;22(10):1892–6. <https://doi.org/10.1111/dom.14134>.
 84. Poirier P, Alpert MA, Fleisher LA, Thompson PD, Sugerman HJ, Burke LE, et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery. *Circulation*. 2009;120(1):86–95. <https://doi.org/10.1161/CIRCULATIONAHA.109.192575>.
 85. Gonzalez A, Barinas J, O'Clairigh C. Substance use: impact on adherence and HIV medical treatment. *Curr HIV/AIDS Rep*. 2011;8(4):223–34. <https://doi.org/10.1007/s11904-011-0093-5>.
 86. Poortinga W. The prevalence and clustering of four major lifestyle risk factors in an English adult population. *Prev Med (Baltim)*. 2007;44(2):124–8. <https://doi.org/10.1016/j.ypmed.2006.10.006>.
 87. Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. *Addiction*. 2006;101(10):1499–508. <https://doi.org/10.1111/j.1360-0443.2006.01543.x>.
 88. Moitra E, Anderson BJ, Herman DS, Hayaki J, Pinkston MM, Kim HN, et al. Examination of using alcohol to cope, depressive symptoms, and perceived social support in persons with HIV and Hepatitis C. *AIDS Care*. 2020 Oct;32(10):1238–45. <https://doi.org/10.1080/09540121.2020.1734177>.

89. Room R. Stigma, social inequality and alcohol and drug use. *Drug Alcohol Rev.* 2005;24(2):143–55. <https://doi.org/10.1080/09595230500102434>.
90. Fazel S, Bains P, Doll H. Substance abuse and dependence in prisoners: a systematic review. *Addiction.* 2006;101(2):181–91. <https://doi.org/10.1111/j.1360-0443.2006.01316.x>.
91. Story A, Murad S, Roberts W, Verheyen M, Hayward AC. Tuberculosis in London: the importance of homelessness. *Problem drug use and prison. Thorax.* 2007;62(8):667–71. <https://doi.org/10.1136/thx.2006.065409>.
92. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. *Curr Diabetes Rev.* 2020;16(5):442–9. <https://doi.org/10.2174/1573399815666191024085838>.
93. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. *Lancet Glob Heal.* 2020;8(8):e1003–17. [https://doi.org/10.1016/S2214-109X\(20\)30264-3](https://doi.org/10.1016/S2214-109X(20)30264-3).
94. Fan VY, Jamison DT, Summers LH. Pandemic risk: how large are the expected losses? *Bull World Health Organ.* 2018;96(2):129–34. <https://doi.org/10.2471/BLT.17.199588>.
95. Nikoloski Z, Alqunaibet AM, Alfawaz RA, Almudarra SS, Herbst CH, El-Saharty S, et al. Covid-19 and non-communicable diseases: evidence from a systematic literature review. *BMC Public Health.* 2021;21(1):1068. Available from: <https://doi.org/10.1186/s12889-021-11116-w>.
96. Xie Y, Hepatitis B. Virus-associated hepatocellular carcinoma. *Adv Exp Med Biol.* 2017;1018:11–21. https://doi.org/10.1007/978-981-10-5765-6_2.
97. World Health Organization. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization; 2011.
98. Islam SMS, Purnat TD, Phuong NTA, Mwingira U, Schacht K, Fröschl G. Non-Communicable Diseases (NCDs) in developing countries: a symposium report. *Global Health.* 2014;10:81.
99. Kostova D, Chaloupka FJ, Frieden TR, Henning K, Paul J, Osewe PL, et al. Noncommunicable disease risk factors in developing countries: policy perspectives. *Prev Med (Baltim).* 2017;105:51–3. <https://doi.org/10.1016/j.ypmed.2017.09.027>.
100. Kostova D, Husain M, Sugerman D, Hong Y, Saraiya M, Keltz J, et al. Synergies between communicable and noncommunicable disease programs to enhance global health security. *Emerg Infect Dis J.* 2017;23(13):S40–467. <https://doi.org/10.3201/eid2313.170581>.
101. Remais JV, Zeng G, Li G, Tian L, Engelgau MM. Convergence of non-communicable and infectious diseases in low- and middle-income countries. *Int J Epidemiol.* 2013;42(1):221–7. <https://doi.org/10.1093/ije/dys135>.
102. Marmot M, Bell R. Social determinants and non-communicable diseases: time for integrated action. *BMJ.* 2019;364:10–2. <https://doi.org/10.1136/bmj.1251>.
103. Hosseinpoor AR, Bergen N, Kunst A, Harper S, Guthold R, Rekve D, et al. Socioeconomic inequalities in risk factors for non communicable diseases in low-income and middle-income countries: results from the world health survey. *BMC Public Health.* 2012;12(1):912. <https://doi.org/10.1186/1471-2458-12-912>.
104. Allen L, Williams J, Townsend N, Mikkelsen B, Roberts N, Foster C, et al. Socioeconomic status and non-communicable disease behavioural risk factors in low-income and lower-middle-income countries: a systematic review. *Lancet Glob Heal.* 2017;5(3):e277–89. [https://doi.org/10.1016/S2214-109X\(17\)30058-X](https://doi.org/10.1016/S2214-109X(17)30058-X).
105. Caul S. Deaths involving COVID-19 by local area and socioeconomic deprivation : deaths occurring between 1 March and 31 July 2020. 2020. Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingcovid19bylocalareasadanddeprivation/deathsoccurringbetween1marchand31july2020>. Accessed 24 June 2021.
106. Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. *J Cranio-Maxillofacial Surg.* 2011;39(2):91–2. <https://doi.org/10.1016/j.jcms.2010.11.001>.
107. Sallis R, Young DR, Tartof SY, Sallis JF, Sall J, Li Q, et al. Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients. *Br J Sports Med.* 2021;0:1–8.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

